Industries / Frontier science / Cell and gene therapy
Living cell medicines
This work makes medicines from living cells, taken from the patient or from a donor, often changed so that they find and attack a chosen target.
7
Milestones achieved, from 1968 to 2024.
2
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
1968
Marrow from a matched sibling
On 24 August 1968 a University of Minnesota team led by immunologist Robert A. Good carried out what the university's health system calls the world's first successful bone marrow transplant from a matched, related donor. The same year, Fritz Bach at the University of Wisconsin transplanted marrow from a sister into her 22-month-old brother, who had an inherited immune disease, Wiskott-Aldrich syndrome; he lived into adulthood. Both teams used Bach's mixed leukocyte culture test, which mixes the white blood cells of patient and donor to check that their tissue types (HLA genes) match. The two reports ran side by side in The Lancet.
Lessondonor cells take only when the tissue types match, and HLA matching became the standard test before a transplant.
Credit
Robert A. Good (University of Minnesota); Fritz Bach (University of Wisconsin)
1989
A receptor built from parts
Gideon Gross, Tova Waks and Zelig Eshhar joined the part of an antibody that recognises a target to the fixed parts of a T-cell receptor, the protein a T cell uses to spot sick cells. T cells carrying this chimeric (mixed-origin) receptor killed cells bearing the chosen target, without the usual need for the target to be displayed by the cell's own tissue-type proteins. This is the design idea behind every CAR-T medicine (CAR stands for chimeric antigen receptor).
Credit
Department of Chemical Immunology, Weizmann Institute of Science, Israel
2012
A child's leukaemia cleared
In 2011 a University of Pennsylvania team reported that a small dose of a patient's own T cells, given a CAR against CD19, a protein on B cells, multiplied more than 1,000-fold in the body and put the patient's chronic lymphocytic leukaemia into a complete remission that was still holding at 10 months. In April 2012 Emily Whitehead, aged 6, became the first child to receive this treatment, at the Children's Hospital of Philadelphia (CHOP), for acute lymphoblastic leukaemia. She developed a severe immune reaction; the team saw a very high level of one signalling protein, IL-6, and gave her tocilizumab, an arthritis drug that blocks it, and she improved within hours. CHOP reported her cancer-free 10 years later.
Lessonthe reaction, now called cytokine release syndrome, can be controlled, and CHOP says tocilizumab is now a standard part of CAR-T care.
Credit
Stephan Grupp (CHOP); Carl June, Bruce Levine and David Porter (Penn Medicine)
2017
Retina cells from skin
A Japanese team reported in 2017 that it had turned skin cells from two patients with wet age-related macular degeneration, an eye disease, into induced pluripotent stem cells (iPSCs, adult cells reset to an embryo-like state), then into a sheet of retinal pigment cells. One of the two received a sheet of their own cells under the retina. A year later the sheet was intact and the patient's eyesight had neither improved nor worsened.
Credit
Michiko Mandai, Masayo Takahashi (RIKEN), Shinya Yamanaka (Center for iPS Cell Research and Application, Kyoto University) and colleagues
2024
T cells for solid tumours
On 16 February 2024 the FDA approved Iovance's Amtagvi for advanced melanoma, which it called the first FDA-approved T-cell therapy taken from a tumour: T cells are separated from a piece of the patient's tumour removed by surgery, grown, and returned in one infusion. Of 73 patients at the approved dose, 31.5% responded. On 2 August 2024 it approved Adaptimmune's Tecelra for synovial sarcoma, the first FDA-approved T-cell receptor therapy: the patient's T cells get a receptor aimed at MAGE-A4, a protein on the cancer cells, and only patients with certain HLA-A*02 tissue types qualify. Of 44 patients, 43.2% responded, for a median of six months.
Credit
Iovance Biotherapeutics; Adaptimmune; FDA
2024
Warning on new T-cell cancers
In November 2023 the FDA said it had reports of T-cell cancers, some carrying the CAR gene itself, in patients treated with CAR-T for blood cancers. FDA officials wrote in February 2024 that they knew of 22 cases among more than 27,000 doses given in the US, and that in 3 cases with gene data the CAR was found in the cancer cells. On 18 April 2024 the FDA required a boxed warning, its strongest label warning, on all approved CAR-T products aimed at CD19 or BCMA, and said treated patients should be monitored for life.
Lessonrare harms from cells that carry an inserted gene can surface only after thousands of doses, so follow-up has to last for life.
Credit
FDA Center for Biologics Evaluation and Research
2024
Donor stromal cells approved
On 18 December 2024 the FDA approved Mesoblast's Ryoncil, which it called the first FDA-approved mesenchymal stromal cell therapy. The cells come from the bone marrow of healthy adult donors, not from the patient. It treats children with acute graft-versus-host disease, an attack by transplanted immune cells on the body, that steroids have not controlled. In a single-arm study of 54 children, 30% had a complete response and 41% a partial response after 28 days.
Credit
Mesoblast; FDA
Watch for
First CAR-T for autoimmunity
Kyverna Therapeutics reported that one dose of its CD19 CAR-T, miv-cel, cut the time 26 patients with stiff person syndrome, a rare autoimmune disease of the nerves, took to walk 25 feet by 46% at week 16 (p = 0.0002), and that 81% improved by at least 20%. 92% had cytokine release syndrome, all of it mild (grade 1 or 2), and 62% had a severe drop in neutrophils, a type of white blood cell. The company planned to file for FDA approval in the first half of 2026. The field has also had setbacks: after three deaths, Novartis paused eight trials of its own CAR-T in autoimmune diseases on 24 August 2026, and Bristol Myers Squibb paused trials of a comparable product.
Achieved whena regulator approves a CAR-T for an autoimmune disease and the benefit holds in follow-up beyond one year.
Claimed by
Kyverna Therapeutics, December 2025
Japan approves iPS cell products
On 6 March 2026 Japan gave conditional, time-limited approval to Sumitomo Pharma's Amchepry, dopamine-making nerve precursor cells grown from donor iPSCs, to improve movement in Parkinson's disease when drugs, including levodopa, no longer work well enough. The approval rests on a study at Kyoto University Hospital; Sumitomo must run a further study to win full approval. A trade report says Japan also approved Cuorips' ReHeart, heart muscle cells from donor iPSCs, on 21 February 2026, and that some researchers question whether such small studies are enough.
Achieved wheneither product wins full approval on the strength of its follow-up study.
Claimed by
Sumitomo Pharma and RACTHERA, March 2026; Cuorips, February 2026
Open
01
CAR-T trials and their results
A free, downloadable table with one row per registered CAR-T or CAR-NK trial, giving the target, the disease, whether the cells are the patient's or a donor's, the receptor's signalling parts where they are reported, the country, the trial's status, and a link to any posted or published result, or "none found". The table refreshes monthly.
The briefCredit · unclaimed02
Living evidence for autoimmune CAR-T
A public page and CSV file, refreshed monthly, with one row per published study of CAR-T in autoimmune disease: disease, product, target, number of patients, follow-up, how many came off all immune drugs, serious side effects and deaths, all as counts from the published papers and company statements.
The briefCredit · unclaimed
Open 01 · the brief
CAR-T trials and their results
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A free, downloadable table with one row per registered CAR-T or CAR-NK trial, giving the target, the disease, whether the cells are the patient's or a donor's, the receptor's signalling parts where they are reported, the country, the trial's status, and a link to any posted or published result, or "none found". The table refreshes monthly.
Why it is still open
A May 2025 review counted 1,580 CAR-T trials on ClinicalTrials.gov as of April 2024 and found published results for about 22% of trials in blood cancers and 15% in immune diseases; it is a one-time analysis. A 2020 Weill Cornell database covered more than 500 CAR trials in 20 countries, but its site, carglobaltrials.com, did not load in November 2026. The Fraunhofer IZI "Living Drugs" wiki lists receptor parts for approved products and some others, entered by hand. None links each trial to its results and stays current.
Built with what exists
The ClinicalTrials.gov API (version 2) and the Chinese and EU trial registries; the Europe PMC API for papers; a large language model such as Claude to draft each row from the papers, with a person checking every field against its source. The note "Findings that cite notes" covers an agent that cites the source behind each finding, the habit this table needs.
First step
Pull every ClinicalTrials.gov record matching the May 2025 review's search, and check that the count comes out near 1,580.
Done looks like
Every CAR-T trial on ClinicalTrials.gov up to a fixed date is in the table, each field is filled or marked "not reported", a second person's check of 50 random rows finds at least 95% of fields match their sources, and the table has refreshed on schedule for three months.
Open 02 · the brief
Living evidence for autoimmune CAR-T
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A public page and CSV file, refreshed monthly, with one row per published study of CAR-T in autoimmune disease: disease, product, target, number of patients, follow-up, how many came off all immune drugs, serious side effects and deaths, all as counts from the published papers and company statements.
Why it is still open
Systematic reviews came out in January 2025 (24 studies, 80 patients), March 2026 (searches to February 2025) and September 2026 (searches to December 2025). Each is a snapshot, and none covers the trial pauses of August 2026. A living review, updated as new studies appear, exists for CAR-T in blood cancers but not for autoimmune disease.
Built with what exists
Saved searches on the Europe PMC API and ClinicalTrials.gov API; a large language model such as Claude to pull counts from each paper, checked by a person; a CSV in a public GitHub repository; a scheduled job (for example GitHub Actions) that rebuilds a static page.
First step
Merge the included-study lists of the January 2025 and March 2026 reviews into one CSV and remove duplicates.
Done looks like
Every study included in the three reviews, plus every newer one, is in the table with a source link per number; a second person's check of 30 random numbers finds at least 95% correct; the page refreshes on schedule for three months running.